4//SEC Filing
Galaini Barbara 4
Accession 0000899243-22-031350
CIK 0001537917other
Filed
Sep 15, 8:00 PM ET
Accepted
Sep 16, 6:00 PM ET
Size
19.8 KB
Accession
0000899243-22-031350
Insider Transaction Report
Form 4
Galaini Barbara
Corporate Controller
Transactions
- Disposition to Issuer
Employee Stock Option - Option to buy
2022-09-16−280,000→ 0 totalExercise: $1.43Exp: 2031-06-13→ Common Stock (280,000 underlying) - Disposition to Issuer
Employee Stock Option - Option to buy
2022-09-16−258,300→ 0 totalExercise: $0.32Exp: 2032-04-21→ Common Stock (258,300 underlying) - Disposition to Issuer
Common Stock
2022-09-16−258,300→ 0 total - Disposition to Issuer
Employee Stock Option - Option to buy
2022-09-16−200,000→ 0 totalExercise: $2.25Exp: 2028-03-22→ Common Stock (200,000 underlying) - Disposition to Issuer
Employee Stock Option - Option to buy
2022-09-16−225,000→ 0 totalExercise: $1.39Exp: 2030-05-06→ Common Stock (225,000 underlying) - Disposition to Issuer
Employee Stock Option - Option to buy
2022-09-16−50,000→ 0 totalExercise: $2.25Exp: 2023-11-07→ Common Stock (50,000 underlying) - Disposition to Issuer
Employee Stock Option - Option to buy
2022-09-16−179,700→ 0 totalExercise: $1.56Exp: 2029-05-02→ Common Stock (179,700 underlying)
Footnotes (7)
- [F1]Disposed of pursuant to the merger agreement between the issuer and Syros Pharmaceuticals, Inc. ("Syros") in exchange for 11,318 shares of Syros common stock having a market value of $7.30 per share at the close of trading on September 15, 2022, the last trading day immediately preceding the effective time of the merger, but after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split"), with cash paid in lieu of fractional shares.
- [F2]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 8,764 shares of Syros common stock for $51.35 per share, after giving effect to the Reverse Split.
- [F3]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $51.35 per share, after giving effect to the Reverse Split.
- [F4]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 7,874 shares of Syros common stock for $35.60 per share, after giving effect to the Reverse Split.
- [F5]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 9,859 shares of Syros common stock for $31.72 per share, after giving effect to the Reverse Split.
- [F6]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 12,269 shares of Syros common stock for $32.63 per share, after giving effect to the Reverse Split.
- [F7]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 11,318 shares of Syros common stock for $7.30 per share, after giving effect to the Reverse Split.
Documents
Issuer
TYME TECHNOLOGIES, INC.
CIK 0001537917
Entity typeother
Related Parties
1- filerCIK 0001751895
Filing Metadata
- Form type
- 4
- Filed
- Sep 15, 8:00 PM ET
- Accepted
- Sep 16, 6:00 PM ET
- Size
- 19.8 KB